Have Seaport Therapeutics insiders bought shares recently?

Yes. Insiders of Seaport Therapeutics (SPTX) filed 1 open-market purchase in the last 90 days; the latest was filed on Nov 4, 2026.

How often do Seaport Therapeutics insiders buy and sell shares?

Since 2026, Seaport Therapeutics insiders reported 1 open-market purchase and 0 sales on Forms 4 and 5, with purchases in 1 different year, most recently 2026.

Who is selling Seaport Therapeutics stock?

No open-market sale by an insider of Seaport Therapeutics (SPTX) was filed with the SEC in the last 90 days.

Do members of Congress trade SPTX?

No trade in Seaport Therapeutics (SPTX) was disclosed by a member of Congress in the last 12 months.

Where does this data come from?

From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.

Seaport Therapeutics (SPTX) insider trading and stock trades

OQRO

Ask OQRO about this page

Ask

Want the short version?

Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.

Explain this page What did insiders at SPTX buy and sell in the last 90 days?Which members of Congress and which funds traded SPTX recently?

Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.

SPTX price and disclosed activity

+0.7% (+$0.14) from May 1, 2026 to Nov 13, 2026 · adjusted daily closes

13F holdings, by quarter end

Insider and Congress marks sit on the trade date stated in the filing; solid is a purchase, hollow a sale. A number means several trades too close to tell apart at this range: pick a shorter range or open it for the list. Fund 13F reports are quarter-end snapshots filed up to 45 days later, so they are shown under the chart across the quarter they describe, not on the price line. Congress amounts are official ranges; mark size uses the lower bound. Past moves are not a forecast.

Show the 1 trade in this range as a list

Denice Torres, Director · Insider purchase, about $99Ktraded Nov 3, 2026, filed Nov 4, 2026

Insider open-market trades, filed in the last 90 days1 buy · 0 sales~$99K boughtInsider trades →Congress trades, disclosed in the last 90 daysNoneNo House or Senate report names this stockCongress →Fund 13F changes, quarter ending Jun 30, 20262 added · 0 cut2 followed funds; holdings as of the quarter end, filed by Aug 14, 2026Fund moves →Federal contracts starting in the last 12 monthsNoneNo award found for this companyContracts →

Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.

Pharmaceutical Preparations company based in Boston, MA. Listed, but no annual report (10-K) filed yet under this SEC registration.

Last 12 months

Not enough history

Market value

$1.07B

Close of Nov 13, 2026 × shares outstanding (per ADS where it applies)

Short interest: 3.73M shares sold short (7.0% of shares outstanding), +0.4% vs the previous count, 17.4 days of normal trading to buy them back. FINRA, as of Oct 30, 2026.

The last year in context

Trading desk

Against the S&P 500 over the year

SPTX +0.7%S&P 500 fund (SPY) +4.7%

Since May 1, 2026, SPTX is up 0.7% and the index fund is up 4.7%: 4 points behind the market. Traders call a stock that beats the index over a period a relative-strength leader.

How much SPTX moves

A usual day: ±3.1%Half of the sessions moved less than this, half moved more.
Daily range (ATR 14): 7.7%Average distance between the low and the high of a session, over the last 14.
Largest one-day fall: −14.3%May 4, 2026
Largest one-day rise: +16.6%Jul 8, 2026
Deepest fall of the year: −42.2%From the close of Aug 26, 2026 to Oct 13, 2026.
Days of 5% or more: 38Out of 136 sessions, in either direction.

End-of-day prices. These figures describe the past year and say nothing about what comes next.

On the public record for Seaport Therapeutics over the 12 months to Nov 14, 2026: 2 clinical trials.

Latest results: quarter ending Sep 30, 2026

Revenue

—

Free cash flow, last 12 months

−$22.7M

This quarter −$22.7M, a year earlier −$15.8M

Net debt

—

Debt —, cash $61.6M, at Sep 30, 2026

Net income, last 12 months

—

From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 2, 2026.

Insider buying and selling since 2026

Insiders of Seaport Therapeutics reported 1 open-market purchase and 0 sales since 2026; purchases in 2026.

Year	Bought	Sold
2026	$99K1×1 trade	—

Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.

Late-stage clinical trials

0 active phase 3 trials and 2 active phase 2 trials led by this company, mostly in major depressive disorder (mdd). The ones with the nearest registered primary completion date still ahead:

Source: ClinicalTrials.gov, studies whose lead sponsor is the company or a listed subsidiary. “Primary completion” is the sponsor's own registry date for the last main data collection. It is not an approval date, it says nothing about the result, and it is often revised.

Latest

See everything

Insider buying

Denice TorresDirector

Filed 10d ago

Bought

~$99K5,000 sh @ $19.87

Traded Nov 3 · filed 1 day later

Since the trade −1.1% · S&P 500 0.0% · to Nov 13

A Seaport Therapeutics director paid $99K out of pocket for Seaport Therapeutics shares.

Want the short version?

Seaport Therapeutics

How this filing works

Questions about Seaport Therapeutics insider trading

Insiders who traded Seaport Therapeutics

Other Pharmaceutical Preparations companies

SPTX price and disclosed activity

The last year in context

Latest results: quarter ending Sep 30, 2026

Insider buying and selling since 2026

Late-stage clinical trials

Latest

~$99K5,000 sh @ $19.87

1.1MShares reported

1.1MShares reported

Late-stage clinical trials

Insider buying and selling since 2026

The last year in context